{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nontuberculous+Mycobacterium+Infection&page=3", "query": { "condition": "Nontuberculous Mycobacterium Infection", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 79, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nontuberculous+Mycobacterium+Infection&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nontuberculous+Mycobacterium+Infection&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T02:37:19.994Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05496374", "title": "A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "SPR720 500 mg", "type": "DRUG" }, { "name": "SPR720 1000 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spero Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2022-12-14", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Fresno, California • Los Angeles, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05496374" }, { "nct_id": "NCT00002309", "title": "A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mycobacterium Avium-Intracellulare Infection", "HIV Infections" ], "interventions": [ { "name": "Azithromycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 3, "location_summary": "San Diego, California • Fort Bragg, North Carolina • Lackland Air Force Base, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Fort Bragg", "state": "North Carolina" }, { "city": "Lackland Air Force Base", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002309" }, { "nct_id": "NCT00111397", "title": "Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mycobacterium Avium-Intracellulare Infection" ], "interventions": [ { "name": "Cytokine therapy", "type": "PROCEDURE" }, { "name": "Interferon Gamma, GM-CSF", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2, "start_date": "2005-05-13", "completion_date": "2010-08-04", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00111397" }, { "nct_id": "NCT00002170", "title": "A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mycobacterium Avium-Intracellulare Infection", "HIV Infections" ], "interventions": [ { "name": "Nelfinavir mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agouron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 5, "location_summary": "San Diego, California • Torrance, California • Chicago, Illinois + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002170" }, { "nct_id": "NCT04921943", "title": "Hypertonic Saline for MAC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Nontuberculous Mycobacterial Lung Disease", "Nontuberculous Mycobacterium Infection" ], "interventions": [ { "name": "Hypertonic saline", "type": "DRUG" }, { "name": "Azithromycin", "type": "DRUG" }, { "name": "Ethambutol", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-05-18", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 2, "location_summary": "New York, New York • Portland, Oregon", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04921943" }, { "nct_id": "NCT01585766", "title": "Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis, Relapsing Forms" ], "interventions": [ { "name": "MEDI-551 30 MG-IV", "type": "DRUG" }, { "name": "MEDI-551 60 MG-SC", "type": "DRUG" }, { "name": "PLACEBO-IV-SC", "type": "DRUG" }, { "name": "MEDI-551 100 MG-IV", "type": "DRUG" }, { "name": "MEDI-551 300 MG-SC", "type": "DRUG" }, { "name": "MEDI-551 600 MG-IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2012-04-24", "completion_date": "2016-06-20", "has_results": true, "last_update_posted_date": "2018-10-29", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585766" }, { "nct_id": "NCT00002101", "title": "A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mycobacterium Avium-Intracellulare Infection", "HIV Infections" ], "interventions": [ { "name": "Ethambutol hydrochloride", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Rifabutin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacia", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 450, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 44, "location_summary": "Phoenix, Arizona • Harbor City, California • Irvine, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Harbor City", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002101" }, { "nct_id": "NCT07021794", "title": "SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-COVID / Long-COVID" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sipavibart", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Nancy Klimas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 100, "start_date": "2025-07-28", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 1, "location_summary": "Fort Lauderdale, Florida", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07021794" }, { "nct_id": "NCT00002140", "title": "A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mycobacterium Avium-intracellulare Infection", "HIV Infections" ], "interventions": [ { "name": "Ethambutol hydrochloride", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Azithromycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 24, "location_summary": "Berkeley, California • Mill Valley, California • Oakland, California + 17 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Mill Valley", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002140" }, { "nct_id": "NCT07301320", "title": "Epetraborole in Patients With Mycobacterium Abscessus Lung Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mycobacterium Abscessus Infection" ], "interventions": [ { "name": "Epetraborole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kevin Winthrop", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2026-03-30", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-03T02:37:19.994Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07301320" } ] }